Lilly Breaks Ground on $3.5 Billion Manufacturing Facility in Pennsylvania
One of four sites announced by Lilly for manufacturing injectable medicines and devices, the Lehigh Valley facility will support the production of obesity treatments, including retatrutide. It is expected to become operational by 2031.



